SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : BCRX: Target practice for shorts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (58)9/6/1999 5:58:00 PM
From: Wolff   of 96
 
FLU-Prevention via Shots-----HMOs are quite unlikely to pay for an antiviral treatment for influenza if the patient has failed to take advantage of the flu shot/FluMist that will undoubtedly be recommended for patients each year. This is a further reduction in the potential market, as people use prescription drugs a whole lot less when they have to pay for 100% of the cost (ask any pharma marketer about this).

Of course, we haven't even addressed the issue of the lack of Phase III trial data or the question of why the BCRX press release only mentioned "reduction in viral load" and did NOT mention any effect in clinical symptom reduction. Perhaps this goes back to the point rasied - if it's not administered very early in infection (which as I've pointed out is next to impossible in the real world outside of clinical trials) the NA inhibitor strategy is too late to be of any clinical benefit.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News